RT Journal Article
SR Electronic
T1 The Generalized 3+3 (G3+3) Design for Phase I Dose-Finding Trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.18.24312178
DO 10.1101/2024.08.18.24312178
A1 Ji, Yuan
A1 Zhang, Yunxuan
A1 Ji, Andrew
YR 2024
UL http://medrxiv.org/content/early/2024/08/19/2024.08.18.24312178.abstract
AB PURPOSE We propose and demonstrate the feasibility and desirability of a novel model-free dose-finding design for phase I clinical trials.METHODS The Generalized 3+3 (G3+3) design uses a set of simple rules summarized as follows: For 3 or 6 patients at a dose, apply the 3+3 design for making dosing decisions. For other numbers, if the observed toxicity rate (OTR) is less than 0.2, escalate to the next higher dose; if the OTR is greater than 0.29, de-escalate to the next lower dose; otherwise, stay at the current dose.RESULTS The G3+3 design is the only design that can replicate the decisions of the 3+3 design for 3 or 6 patients among the popular designs compared like BOIN and i3+3. G3+3 generates desirable decisions when the number of patients treated is not 3 or 6, like the popular designs. Computer simulation verifies the superior operating characteristics of the G3+3 design.CONCLUSION The G3+3 design generalizes the popular 3+3 design so that desirable decisions can be made for any number of patients at a dose. G3+3 does not rely on statistical models, is simple and transparent, and can be implemented without a software tool. Therefore, it is expected to facilitate and enhance modern phase I dose-finding trials and early-phase drug development.Competing Interest StatementYuan Ji declares the following competing interests. 1.Former Co-Founder of Laiya Consulting, Inc., a statistical company providing consultation and software service for pharmaceutical and biotech industry. Laiya has been acquired by Cytel in 2020. 2.Co-Founder of Bayesoft Inc., a statistical company providing consultation and software service for pharmaceutical and biotech industry. 3.IDMC member for Astellas, Boehringer Ingelheim and Lyell. 4.Research contracts with Sanofi. 5.Executive Advisor for Cytel Inc. Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThere is no data in the article since it is about a statistical design for phase I clinical trials.